Quarterly Result15 May 2025, 10:52 pm
Biocon Ltd Achieves 15% YoY Growth in Q4 FY25 Operating Revenue
AI Summary
Biocon Ltd has reported a robust 15% year-over-year (YoY) and 16% sequential growth in operating revenue on a like-for-like basis in Q4 FY25. The growth was driven by strong performance in Generics, steady progress in Biosimilars, and ongoing traction in Research Services. The Generics business had the strongest quarter in FY25 with a 46% YoY and 53% sequential growth. The company also received approvals for Liraglutide in the EU and Everolimus (Zortress®) tablets in the U.S., and commenced supplies of Tacrolimus to China.
Key Highlights
- Biocon Ltd achieves 15% YoY and 16% sequential growth in operating revenue on a like-for-like basis in Q4 FY25
- Generics business reports the strongest quarter in FY25 with 46% YoY and 53% sequential growth
- Company receives approvals for Liraglutide in the EU and Everolimus (Zortress®) tablets in the U.S.
- Biocon commences supplies of Tacrolimus to China
- Core EBITDA for the quarter stands at INR 1,363 crores with a healthy core operating margin of 31%